In a lengthy front page story today, The Legal Intelligencer explored the current state of lawsuits involving testosterone replacement drugs that have been demonstrated to increase the risks of cardiovascular problems in older men.
The article noted that Ross Feller Casey has already filed six so-called “Low T” lawsuits in Philadelphia on behalf of men from across the country who have suffered heart attacks, strokes or other serious events while on testosterone containing drugs. They are the only such lawsuits filed in Philadelphia to date.
But Dr. Mark A. Hoffman, a lawyer at Ross Feller Casey, told the paper that there are many more on the way.
Hoffman said that the firm is “currently investigating well over 100 cases at this point and we’ve had contact with other law firms to work as local counsel.”
“I think we’re right at the beginning at what will be a substantial number of cases,” he said, adding that Ross Feller Casey is looking to file cases out of state as well.
“We’re keeping our options open on where we could file out-of-state cases,” said Hoffman, an internationally respected physician and trial lawyer who specializes in mass tort litigation involving drugs and medical devices.
He went on to tell the paper that it appears Abbott Laboratories and its subsidiary, AbbVie Pharmaceuticals, had 60 to 70 percent of the market share, with its drug AndroGel, “so we’re looking at all of our options including state court out in Illinois” where Abbott is based.
To learn more, go to www.rossfellercasey.com/practice-areas/lowtlawsuit/